CAS: 157810-81-6; (S)-1-((2S,4R)-4-Benzyl-2-Hydroxy-5-(((1S,2R)-2-Hydroxy-2,3-Dihydro-1H-Inden-1-yl)Amino)-5-Oxopentyl)-N-(Tert-Butyl)-4-(Pyridin-3-Ylmethyl)Piperazine-2-Carboxamide Sulfate

该化合物是一种主要用于治疗HIV-1感染的强效蛋白抑制剂,其化学结构能够选择性地对病毒蛋白酶具有约束力,有效抑制病毒多蛋白的分裂,防止病毒成熟;硫酸盐形式能提高溶解性和生物利用率,确保持续的药用动力性能;天然硫酸盐的特征是其高度特殊性和与其他抗逆转录病毒剂的交叉抗药性低,使其成为复方疗法中的宝贵成分;通常通过受控配方进行施用,以优化治疗效力,同时尽量减少不利影响;适当的储存和处理对于在建议的条件下保持其稳定性和能性至关重要.

结构式图片

欧盟法规

C&L通报

合成工艺路线路线简述

    (S)-1-[(2S,4R)-4-Benzyl-5-((3As,8Ar)-2,2-Dimethyl-8,8A-Dihydro-3Ah-Indeno[1,2-D]Oxazol-3-yl)-2-Hydroxy-5-Oxo-Pentyl]-4-Pyridin-3-Ylmethyl-Piperazine-2-Carboxylic Acid Tert-Butylamide 以90的收率获得硫酸茚地那韦
    参考文献: Process To Make Hiv Protease Inhibitor From 2(S)-4-Picolyl-2-Piperazine-T-Butylcarboxamide[fr] Procede De Fabrication D'Un Inhibiteur De La Protease Du Virus Vih A Partir Du 2(S)-4-Picolyl-2-Piperazine-T-Butylcarboxamide
    标题: Process To Make Hiv Protease Inhibitor From 2(S)-4-Picolyl-2-Piperazine-T-Butylcarboxamide[fr] Procede De Fabrication D'Un Inhibiteur De La Protease Du Virus Vih A Partir Du 2(S)-4-Picolyl-2-Piperazine-T-Butylcarboxamide
    摘要:一个制作临床有效的hiv蛋白酶抑制剂的过程,通过使用2(S)-4-吡啶基-2-哌嗪基-T-丁基羧酰胺作为中间体,通过另一种汇合合成方法来消除其合成中的一步;如上所示.

    海关参考信息

    专利信息


    专利号:US-8987493-B2
    优先权日:2010-05-20
    标题 :Process for synthesis of silane dipeptide analogs
    发明人:SIEBURTH SCOTT MCNEILL; BO YINGJIAN
    权利人:SIEBURTH SCOTT MCNEILL; BO YINGJIAN; Temple University—Of the Commonwealth System of Higher Education
    摘要:The invention provides a method of preparing silane dipeptide analogs, comprising the steps of treating a solution of a substituted 1,2-oxasilolane with lithium metal to form a solution of the dilithium salt of a substituted 3-hydroxypropylsilanol, and reacting the solution of the dilithium salt of the substituted 3-hydroxypropylsilanol with a substituted enamine.

    专利号:US-2025206743-A1
    优先权日:2022-03-25
    标 题:Tyk2 inhibitor synthesis and intermediates thereof
    发明人:MASSE CRAIG E; PHADKE AVINASH S; LAWSON JON P; LEVY STUART; YANG XIAOWEI; WU GUISHENG; FAN SHUFENG
    权利人:TAKEDA PHARMACEUTICALS CO
    摘要:Described herein are methods of synthesis of a tyrosine-protein kinase 2 (TYK2) inhibitor and to intermediate compounds of the synthesis and methods of making the intermediates. Also provided are pharmaceutically acceptable compositions including compounds prepared by the synthetic method and methods of treating disorders using the same.

    专利号:US-8557979-B2
    优先权日:2004-06-10
    标题 :Carbapenem antibacterials with gram-negative activity and processes for their preparation
    发明人:CHOI WOO-BAEG; KOWALIK EWA
    权利人:CHOI WOO-BAEG; KOWALIK EWA; FOB SYNTHESIS INC
    摘要:The present invention provides β-methyl carbapenem compounds and pharmaceutical compositions useful in the treatment of bacterial infections and methods for treating such infections using such compounds and/or compositions. The invention includes administering an effective amount of a carbapenem compound or salt and/or prodrug thereof to a host in need of such a treatment. The present invention is also in the field of synthetic organic chemistry and is specifically provides an improved method of synthesis of β-methyl carbapenems which are useful as antibacterial agents.

    专利号:US-6869973-B2
    优先权日:2000-06-22
    标题:Nitrosated and nitrosylated taxanes, compositions and methods of use
    发明人:GARVEY DAVID S; LETTS L GORDON; LIN CHIA-EN; RICHARDSON STEWART K; WANG TIANSHENG
    权利人:NITROMED INC
    摘要:The present invention describes novel nitrosated and/or nitrosylated taxanes, and novel compositions comprising at least one nitrosated and/or nitrosylated taxane, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The present invention also provides novel compositions comprising at least one taxane and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The compounds and compositions of the present invention can also be bound to a matrix. The present invention also provides methods for treating or preventing cardiovascular diseases and disorders, autoimmune diseases, pathological conditions resulting from abnormal cell proliferation, polycystic kidney disease, inflammatory disease, preserving organs and/or tissues or to inhibit wound contraction, particularly the prophylactic and/or therapeutic treatment of restenosis, by administering nitrosated and/or nitrosylated taxane or parent taxanes in combination with nitric oxide donors that are capable of releasing nitric oxide or indirectly delivering or transferring nitric oxide to targeted sites under physiological conditions.

    专利号:US-2003203915-A1
    优先权日:2002-04-05
    标题 :Nitric oxide donors, compositions and methods of use related applications
    发明人:FANG XINQIN; GARVEY DAVID S; GASTON RICKY D; LIN CHIA-EN; RANATUNGA RAMANI R; RICHARDSON STEWART K; WANG TIANSHENG; WANG WEIHENG; WEY SHIOW-JYI
    权利人:FANG XINQIN; GARVEY DAVID S; GASTON RICKY D; LIN CHIA-EN; RANATUNGA RAMANI R; RICHARDSON STEWART K; WANG TIANSHENG; WANG WEIHENG; WEY SHIOW-JYI
    摘要:The invention describes novel nitric oxide donors and novel compositions comprising at least one nitric oxide donor. The invention also provides novel compositions comprising at least one nitric oxide donor, and, optionally, at least one therapeutic agent. The compounds and compositions of the invention can also be bound to a matrix. The invention also provides methods for treating cardiovascular diseases, for the inhibition of platelet aggregation and platelet adhesion caused by the exposure of blood to a medical device, for treating pathological conditions resulting from abnormal cell proliferation; transplantation rejections, autoimmune, inflammatory, proliferative, hyperproliferative, vascular diseases; for reducing scar tissue or for inhibiting wound contraction, particularly the prophylactic and/or therapeutic treatment of restenosis by administering the nitric oxide donor optionally in combination with at least one therapeutic agent. The invention also provides methods for treating inflammation, pain, fever, gastrointestinal disorders, respiratory disorders and sexual dysfunctions. The nitric oxide donors donate, transfer or release nitric oxide, and/or elevate endogenous levels of endothelium-derived relaxing factor, and/or stimulate endogenous synthesis of nitric oxide and/or are substrates for nitric oxide synthase and are capable of releasing nitric oxide or indirectly delivering or transferring nitric oxide to targeted sites under physiological conditions. The therapeutic agent can optionally be substituted with at least one NO and/or NO 2 group (i.e., nitrosylated and/or nitrosated). The invention also provides novel compositions and kits comprising at least one nitric oxide donor and/or at least one therapeutic agent.

    专利号:US-10933051-B2
    优先权日:2017-06-09
    标 题 :Carbapenem compounds and compositions for the treatment of bacterial infections
    发明人:CHOI WOO-BAEG; TOMIOKA TAKASHI; JOO HYUNG-YEUL; TRUONG PHONG; MIN BRIAN
    权利人:FOB SYNTHESIS INC
    摘要:The present invention provides carbapenem compounds and pharmaceutical compositions useful in the treatment of bacterial infections, including drug resistant or multiple-drug resistant bacterial infections, and methods for treating such infections using such compounds and/or compositions. The invention includes administering an effective amount of a carbapenem compound or salt and/or prodrug thereof to a host in need of such a treatment.
    安徽贝克联合制药有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.bcpharm.com
    电话: 40018781990558-8629371👤
    📞安徽贝克联合制药有限公司 ⚠️参考联系方式

    销售电话:40018781990558-8629371
    邮箱:sales@bcpharm.com
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    郑州佰宇药业有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.zzbaiyu.com
    企业联系电话:13938569199👤
    📞郑州佰宇药业有限公司 ⚠️参考联系方式
    联系人:陈经理
    电话:13938569199


    邮箱:13938569199@163.com
    通信地址: 河南省郑州市新郑市龙湖镇小刘桥百鸿机电市场C3区22号
    邮编: 450000
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:河南省郑州市新郑市龙湖镇小刘桥百鸿机电市场C3区22号
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页
    现货

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Rao RN, Vali RM, Raju SS. Liquid chromatography tandem mass spectrometric studies of indinavir sulphate and its forced degradation products. J Pharm Biomed Anal. 2013 Feb 23;74:101-10. doi: 10.1016/j.jpba.2012.10.025. Epub 2012 Oct 29. doi: 10.1007/s11255-010-9751-6. Epub 2010 May 11.
    3: Jann MW, Spratlin V, Momary K, Zhang H, Turner D, Penzak SR, Wright A, VanDenBerg C. Lack of a pharmacokinetic drug-drug interaction with venlafaxine extended-release/indinavir and desvenlafaxine extended-release/indinavir. Eur J Clin Pharmacol. 2012 May;68(5):715-21. doi: 10.1007/s00228-011-1180-7. Epub 2011 Dec 16. Reduced indinavir exposure during pregnancy. Br J Clin Pharmacol. 2013 Sep;76(3):475-83. doi: 10.1111/bcp.12078.
    5: Barrail-Tran A, Taburet AM, Poirier JM; Groupe Suivi Therapeutique Pharmacologique de la Societe Francaise de Pharmacologie et de Therapeutique. [Evidence-based therapeutic drug monitoring for indinavir]. Therapie. 2011 May-Jun;66(3):239-46. doi: 10.2515/therapie/2011035. Epub 2011 Aug 9. Review. French. doi: 10.1016/j.ejps.2013.01.012. Epub 2013 Feb 9. HIV-1 fitness landscape models for indinavir treatment pressure using observed evolution in longitudinal sequence data are predictive for treatment failure. Infect Genet Evol. 2013 Oct;19:349-60. doi: 10.1016/j.meegid.2013.03.014. Epub 2013 Mar 21. doi: 10.1097/ALN.0b013e3182423478.

    合成参考文献


    摘要:Gekkan Yakuji. Pharmaceuticals Monthly., 39(2167), 1997
    摘要:Brandmann M et al; J Neurochem 120 (1): 78-92 (2012)
    摘要:Drug Facts and Comparisons 2011. Wolters Kluwer Health St. Louis, MO 2011, p. 2449
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知